Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Xiao-Dong Zhou,Seung Up Kim,Terry Cheuk-Fung Yip,Salvatore Petta,Atsushi Nakajima,Emmanuel Tsochatzis,Jérôme Boursier,Elisabetta Bugianesi,Hannes Hagström,Wah Kheong Chan,Manuel Romero-Gomez,José Luis Calleja,Victor de Lédinghen,Laurent Castéra,Arun J Sanyal,George Boon-Bee Goh,Philip N Newsome,Jiangao Fan,Michelle Lai,Céline Fournier-Poizat,Hye Won Lee,Grace Lai-Hung Wong,Angelo Armandi,Ying Shang,Grazia Pennisi,Elba Llop,Masato Yoneda,Marc de Saint-Loup,Clemence M Canivet,Carmen Lara-Romero,Rocio Gallego-Duràn,Amon Asgharpour,Kevin Kim-Jun Teh,Sara Mahgoub,Mandy Sau-Wai Chan,Huapeng Lin,Wen-Yue Liu,Giovanni Targher,Christopher D Byrne,Vincent Wai-Sun Wong,Ming-Hua Zheng
DOI: https://doi.org/10.1136/gutjnl-2024-333074
IF: 24.5
2024-10-08
Gut
Abstract:Background Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). Aim To explore the effects of statins on the long-term risk of all-cause mortality, liver-related clinical events (LREs) and liver stiffness progression in patients with MASLD. Methods This cohort study collected data on patients with MASLD undergoing at least two vibration-controlled transient elastography examinations at 16 tertiary referral centres. Cox regression analysis was performed to examine the association between statin usage and long-term risk of all-cause mortality and LREs stratified by compensated advanced chronic liver disease (cACLD): baseline liver stiffness measurement (LSM) of ≥10 kPa. Liver stiffness progression was defined as an LSM increase of ≥20% for cACLD and from <10 kPa to ≥10 or LSM for non-cACLD. Liver stiffness regression was defined as LSM reduction from ≥10 kPa to <10 or LSM decrease of ≥20% for cACLD. Results We followed up 7988 patients with baseline LSM 5.9 kPa (IQR 4.6–8.2) for a median of 4.6 years. At baseline, 40.5% of patients used statins, and cACLD was present in 17%. Statin usage was significantly associated with a lower risk of all-cause mortality (adjusted HR=0.233; 95% CI 0.127 to 0.426) and LREs (adjusted HR=0.380; 95% CI 0.268 to 0.539). Statin usage was also associated with lower liver stiffness progression rates in cACLD (HR=0.542; 95% CI 0.389 to 0.755) and non-cACLD (adjusted HR=0.450; 95% CI 0.342 to 0.592), but not with liver stiffness regression (adjusted HR=0.914; 95% CI 0.778 to 1.074). Conclusions Statin usage was associated with a relatively lower long-term risk of all-cause mortality, LREs and liver stiffness progression in patients with MASLD.
gastroenterology & hepatology